Palonosetron, nimesulide, Gelclair^®, netupitant, anamorelin, ipamorelin, elsiglutide and the other pharmaceutical compounds in our commercial and development pipeline represent tangible result of the high performance of the Helsinn business model which differentiates Helsinn from other pharmaceutical groups. 

Helsinn pinpoints innovative pharmaceutical products and medical devices in the early development phase and in-licenses the candidate by acquiring the worldwide rights.

Through self-financing, management and development of its products, Helsinn has established a valuable international market position.

The Group provides technological and scientific infrastructures for pre-clinical, clinical and industrial development, according to the highest scientific, quality and ethical standards, and in full compliance with U.S. FDA and EU EMA requirements.

As soon as the development phase is completed, with the attainment of the registration in US, Europe, Japan and other markets, Helsinn’s product is ready for worldwide distribution and sale through an established network of international partners supported by the Group’s logistic infrastructure and post-marketing services.

Helsinn has a large product development capability ranging from lead optimization, preclinical research and throughout all phases of clinical development with a proven expertise in cancer supportive care, oncology, pain and inflammation, and gastroenterology.